for people ages 30-85 (full criteria)
at Irvine, California and other locations
study started
completion around



This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.

Official Title

Phase 2b/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Dipraglurant (ADX48621) for the Treatment of Dyskinesia in Patients With Parkinson's Disease Receiving Levodopa-based Therapy


Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias, Parkinson's disease, Dyskinesia, Levodopa-induced Dyskinesia, Drug-Induced Dyskinesia, Dipraglurant, Dipraglurant TID


You can join if…

Open to people ages 30-85

  • Patients with Parkinson's Disease on a stable regimen of antiparkinson's medications, including a levodopa preparation administered not less than 3 times daily.
  • Meet protocol-specified criteria for moderate to severe dyskinesia symptoms based on UDysRS and Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) assessments.
  • Meet protocol specified criteria for ON time with troublesome dyskinesia based on a standard PD home diary.

You CAN'T join if...

  • Prior surgical treatment for Parkinson's Disease (e.g., deep brain stimulation).
  • Other neurological disease (including psychiatric disease and/or cognitive impairment) that, in the opinion of the investigator, would affect the patient's ability to complete study assessments.
  • Other significant medical condition that may affect the safety of the patient or preclude adequate participation in the study.
  • Pregnant or breast-feeding. Female patients who are of child-bearing potential must be using adequate contraceptive methods (e.g. oral contraceptive, double-barrier method, intra-uterine device, intra-muscular hormonal contraceptive), and have a negative pregnancy test at Screening.

    Other protocol-defined inclusion and exclusion criteria may apply


  • University of California Irvine Medical Center accepting new patients
    Irvine California 92697 United States
  • Pacific Neuroscience Institute accepting new patients
    Torrance California 90503 United States


accepting new patients
Start Date
Completion Date
Addex Pharma S.A.
Phase 2/3 research study
Study Type
Expecting 140 study participants
Last Updated